Exelixis, Inc. EXEL today announced the presentation of
positive overall survival (OS) results from coBRIM, the phase 3 pivotal
trial evaluating COTELLIC™ (cobimetinib) in patients with
previously untreated resectable, locally advanced or metastatic melanoma
carrying a BRAF V600E or V600K mutation, in combination with
vemurafenib. Dr. Victoria Atkinson, Medical Oncologist at Princess
Alexandra Hospital, Queensland, Australia, presented the data during a
late-breaking abstract oral presentation this afternoon at the Society
for Melanoma Research (SMR) 2015 International Congress, which is being
held November 18-21 in San Francisco. COTELLIC is a selective inhibitor
of MEK that was discovered by Exelixis and is now the subject of a
worldwide collaboration agreement between Exelixis and Genentech, a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in